Nasdaq GlobeNewswire

RedHill Biopharma Provides 2017 Semi-Annual Business Update

Del

TEL-AVIV, Israel, 2017-01-12 12:01 CET (GLOBE NEWSWIRE) --

RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today provided an update on key programs, potential milestones and estimated timelines.

Micha Ben Chorin, RedHill’s CFO, said: “We are heading into 2017 with important potential catalysts in the coming months and with several ongoing Phase III and Phase II programs for gastrointestinal indications. Following the recently announced U.S. co-promotion agreement for Donnatal®1, RedHill is advancing its strategic transition into a revenue-generating, gastrointestinal-focused, specialty pharmaceutical company with commercial presence in the U.S. This transition is planned to support potential future commercialization of RedHill’s Phase III-stage gastrointestinal drugs, if approved by the FDA. We are backed by strong institutional investors and maintain a debt-free balance sheet with approximately $70 million in cash, allowing us to continue to diligently execute our plans.”

RHB-105 - H. pylori bacterial infection (confirmatory Phase III)

  • The confirmatory Phase III study with RHB-105 for the treatment of H. pylori infection, expected to enroll 440 patients in up to 55 U.S. sites, is planned to be initiated by April 2017 following completion of an ongoing supportive pharmacokinetic (PK) program.

RHB-104 - Crohn’s disease (Phase III)

  • 254 of the planned total of 410 subjects have been enrolled to date in the randomized, double-blind, placebo-controlled first Phase III study in the U.S. and additional countries with RHB-104 for Crohn’s disease (the MAP US study).
     
  • A second independent data and safety monitoring board (DSMB) meeting of the MAP US study is expected in the second quarter of 2017, with an interim efficacy analysis and an option for early stop for success for overwhelming efficacy.

BEKINDA® (RHB-102) - acute gastroenteritis (Phase III) and IBS-D (Phase II)

  • 291 of the planned total of 320 subjects have been enrolled to date in the randomized, double-blind, placebo-controlled Phase III clinical study with BEKINDA® 24 mg in the U.S. for acute gastroenteritis and gastritis (the GUARD study). Top-line results are expected by mid-2017.
     
  • 83 of the planned total of 120 subjects have been enrolled to date in the randomized, double-blind, placebo-controlled Phase II clinical study with BEKINDA® 12 mg for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D). Top-line results are expected in mid-2017.

YELIVA® - Phase I/II studies for multiple oncology and inflammatory indications

  • RedHill is currently pursuing several Phase I/II clinical studies with YELIVA® in the U.S., targeting oncology indications, with support from National Cancer Institute (NCI) grants awarded to Apogee Biotechnology and U.S. universities, including ongoing studies for advanced hepatocellular carcinoma (Medical University of South Carolina), refractory or relapsed multiple myeloma (Duke University Medical Center) and refractory/relapsed diffuse large B-cell lymphoma and Kaposi sarcoma (Louisiana State University Health Sciences Center).
     
  • Additional Phase I/II studies with YELIVA® are in various stages of preparation, including a Phase Ib study to evaluate YELIVA® as a radioprotectant for prevention of mucositis in head and neck cancer patients undergoing therapeutic radiotherapy, planned to be initiated in the first half of 2017.

Donnatal® (Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide)

  • As part of RedHill’s strategic transition into a revenue-generating, gastrointestinal-focused, specialty pharmaceutical company with a commercial presence in the U.S., the Company entered earlier this month into an exclusive co-promotion agreement with a subsidiary2 of Concordia International Corp. (NASDAQ:CXRX) (TSX:CXR), granting RedHill certain U.S. promotion rights for Donnatal®, a prescription oral drug used with other drugs in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis (inflammation of the small bowel)3. RedHill expects to initiate promotion of Donnatal® in the coming months.

RIZAPORT® (RHB-103) - acute migraines (approved for marketing in Germany)

  • Re-submission of the RIZAPORT® NDA to the FDA is expected in the first half of 2017. RIZAPORT® was approved for marketing in Germany under the European Decentralized Procedure (DCP) in October 2015 and a first commercialization agreement was signed with Grupo JUSTE S.A.Q.F for Spain and a second commercialization agreement was signed with Pharmatronic Co. for South Korea. RedHill continues discussions with additional potential commercialization partners for RIZAPORT® in the U.S., Europe and other territories.

About Donnatal®:
Donnatal® (Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide), a prescription drug, is classified as possibly effective as an adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. Donnatal® slows the natural movements of the gut by relaxing the muscles in the stomach and intestines and acts on the brain to produce a calming effect. Donnatal® comes in two formulations: immediate release Donnatal® Tablets and immediate release Donnatal® Elixir, a fast acting liquid.

Donnatal® is contraindicated in patients who have glaucoma, obstructive uropathy, obstructive disease of the gastrointestinal tract, paralytic ileus, unstable cardiovascular status, severe ulcerative colitis, myasthenia gravis, hiatal hernia with reflux esophagitis, or known hypersensitivity to any of the ingredients. Patients who are pregnant or breast-feeding or who have autonomic neuropathy, hepatic or renal disease, hyperthyroidism, coronary heart disease, congestive heart failure, cardiac arrhythmias, tachycardia or hypertension should notify their doctor before taking Donnatal®. Side effects may include: dryness of the mouth, urinary retention, blurred vision, dilation of pupils, rapid heartbeat, loss of sense of taste, headache, nervousness, drowsiness, weakness, dizziness, insomnia, nausea, vomiting and allergic reactions which may be severe.

Further information, including prescribing information, can be found on www.donnatal.com.

Please see the following website for important safety information about Donnatal®http://www.donnatal.com/professionals/important-safety-information/

About RedHill Biopharma Ltd.:      
RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) is a specialty biopharmaceutical company headquartered in Israel, primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. RedHill has a U.S. co-promotion agreement with Concordia for Donnatal®, a prescription oral adjunctive drug used in the treatment of IBS and acute enterocolitis. RedHill’s clinical-stage pipeline includes: (i) RHB-105 - an oral combination therapy for the treatment of Helicobacter pylori infection with successful results from a first Phase III study; (ii) RHB-104 - an oral combination therapy for the treatment of Crohn's disease with an ongoing first Phase III study, a completed proof-of-concept Phase IIa study for multiple sclerosis and a QIDP status for NTM; (iii) BEKINDA® (RHB-102) - a once-daily oral pill formulation of ondansetron with an ongoing Phase III study for acute gastroenteritis and gastritis and an ongoing Phase II study for IBS-D; (iv) RHB-106 - an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; (v) YELIVA® (ABC294640) - a Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory and gastrointestinal indications; (vi) MESUPRON - a Phase II-stage first-in-class, orally-administered uPA inhibitor, targeting gastrointestinal and other solid tumors and (vii) RIZAPORT® (RHB-103) - an oral thin film formulation of rizatriptan for acute migraines, with a U.S. NDA currently under discussion with the FDA and marketing authorization received in Germany in October 2015. More information about the Company is available at: www.redhillbio.com.

1 Donnatal® (Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide) is a prescription drug, classified as possibly effective as an adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis.

2 Concordia Pharmaceuticals Inc.

3 This drug has been evaluated as possibly effective for these indications. For more information, please see the prescribing information: http://www.donnatal.com/wp-content/uploads/2015/02/2015-02-18-Risk-Benefit-information-DTC-REV.-SE.pdf.

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company’s research, manufacturing, preclinical studies, clinical trials, and other therapeutic candidate development efforts; (ii) the Company’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; (iii) the extent and number of additional studies that the Company may be required to conduct and the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company’s therapeutic candidates; (v) the Company’s ability to establish and maintain corporate collaborations; (vi) the Company's ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (vii) the interpretation of the properties and characteristics of the Company’s therapeutic candidates and of the results obtained with its therapeutic candidates in research, preclinical studies or clinical trials; (viii) the implementation of the Company’s business model, strategic plans for its business and therapeutic candidates; (ix) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (x) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xi) estimates of the Company’s expenses, future revenues capital requirements and the Company’s needs for additional financing; (xii) competitive companies and technologies within the Company’s industry; and (xiii) the impact of the political and security situation in Israel on the Company's business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the SEC on February 25, 2016. All forward-looking statements included in this Press Release are made only as of the date of this Press Release. We assume no obligation to update any written or oral forward-looking statement unless required by law.

         Company contact:
         Adi Frish
         Senior VP Business Development &
         Licensing
         RedHill Biopharma
         +972-54-6543-112
         adi@redhillbio.com
         
         IR contact (U.S.):
         Marcy Nanus
         Senior Vice President
         The Trout Group
         +1-646-378-2927
         Mnanus@troutgroup.com

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

David Crosby Announces Intent to License His Name to the Cannabis Industry18.7.2018 18:04Pressemelding

Music industry icon pursuing licensing partnership with a leading Cannabis company LOS ANGELES and TORONTO, July 18, 2018 (GLOBE NEWSWIRE) -- David Crosby, co-founder of two of the most successful bands in history (Crosby, Stills, Nash & Young, and The Byrds) today announced he is seeking a licensing relationship with a national or global Cannabis company. This opportunity would include the exclusive license of his iconic name and marks for use worldwide. Mr. Crosby suggests calling the brand "MIGHTY CROZ" because his friends, colleagues and fans call him "Croz", but specific naming and packaging will be determined in consultation with the selected Cannabis company. Mr. Crosby will actively advise the selected Cannabis company in developing and marketing the brand. "People have been asking me to do a quality Cannabis brand and with legalization expanding, now is the right time," said David Crosby from his ranch in California. "Our first priority is partnering with a leading Cannabis co

Telecom Argentina's landing station and backhaul are selected for ARBR submarine cable system between Argentina & Brazil18.7.2018 17:00Pressemelding

ARBR + Seabras-1 to provide most direct route between Buenos Aires & New York BUENOS AIRES, Argentina and BOSTON, July 18, 2018 (GLOBE NEWSWIRE) -- Telecom Argentina S.A. ("Telecom Argentina") (BASE:TECO2) (NYSE:TEO), one of Argentina's leading telecommunications companies, Grupo Werthein, a preeminent Argentine investment holding company with a track record of significant telecommunications holdings, and Seaborn Networks ("Seaborn"), a leading developer-owner-operator of submarine fiber optic cable systems, announced today that the ARBR submarine cable system between Argentina and Brazil ("ARBR") will be landing in Telecom Argentina's cable landing station in Las Toninas, Argentina. In addition, Telecom Argentina shall provide ARBR with dark fiber on a backhaul route between Las Toninas and Buenos Aires, as well as point of presence (POP) space in Buenos Aires. ARBR is a new fiber optic submarine cable system developed by Seaborn and co-owned by Seaborn's Seabras Group together with T

Salim Ismail Announced as Keynote Speaker at Mitratech's Interact 2018 Conference18.7.2018 15:02Pressemelding

Best-Selling Author and Tech Strategist Shares Insights on New Paradigm in Organizational Design AUSTIN, Texas, July 18, 2018 (GLOBE NEWSWIRE) -- Mitratech, the leading provider of legal and compliance software solutions, today announced that Salim Ismail, best-selling author, founding executive director of Singularity University, and founder of ExO Works, will deliver the keynote address at its Interact 2018 Conference. Every year the Interact conference provides an opportunity for clients, industry experts and partners to connect, learn, and contribute to insightful sessions on Mitratech innovations, legal operations best practices and industry trends. This year's theme, The Next Frontier of Legal Ops, recognizes that legal operations should be a center of innovation and excellence that brings people, processes and information together like never before by extending legal operations capabilities across the entire enterprise. "Salim understands the power of innovation and technology t

Corvil Introduces AI-Powered "Intelligence Hub" to Help Businesses Achieve Superior Digital Experiences and Performance18.7.2018 15:00Pressemelding

The solution delivers powerful big data analytics insights to business and operational users without the traditional lengthy timelines and costs DUBLIN, Ireland, July 18, 2018 (GLOBE NEWSWIRE) -- Corvil today announced Intelligence Hub, the next generation of digital intelligence to improve the performance, agility and digital experience of today's modern businesses. Intelligence Hub offers the potential to dramatically change how organizations see, manage and optimize their business and supporting technology operations. Today's businesses require a new type of "digital intelligence" that understands and correlates changes in the critical dimensions of business outcomes, user and customer experience, underlying application and infrastructure performance, and cybersecurity. Intelligence Hub provides proactive alerting on changes in these dimensions and allows business and operations teams to flexibly visualize, explore and analyze this key information for more informed action. " Intelli

Taconic Biosciences and Cyagen Biosciences Announce Strategic Partnership18.7.2018 14:00Pressemelding

RENSSELAER, N.Y., July 18, 2018 (GLOBE NEWSWIRE) -- Taconic Biosciences and Cyagen Biosciences, global leaders in the generation of custom genetically engineered rodent models and associated services, announced a strategic partnership. Under the agreement terms, the two companies will combine resources to provide the global scientific community with access to premium custom model design and generation services backed by comprehensive capabilities and cutting-edge, fully-licensed technologies. Custom animal models play a critical role in new drug discovery as biological systems that provide critical insight into the dynamic between a potential therapeutic and a living organism. Combining over twenty years of experience, the industry's most extensive model generation technology portfolio, and seamless integration to downstream premium custom breeding solutions, Taconic is recognized for creating complex genetically engineered mice and rats for biomedical research. Cyagen entered the indu

Data to be Presented From Biogen's Alzheimer's Disease Clinical Development Portfolio at the 2018 Alzheimer's Association International Conference (AAIC)18.7.2018 13:30Pressemelding

Ongoing Alzheimer's disease research programs target possible causes of the disease through multiple modalities Data to be presented from Alzheimer's disease clinical development portfolio including aducanumab, elenbecestat, and BAN2401 Data underscore Biogen's long-term commitment to furthering Alzheimer's disease research and treatment, with a focus on patients with early stage disease CAMBRIDGE, Mass., July 18, 2018 (GLOBE NEWSWIRE) -- Biogen (Nasdaq:BIIB) announced it will present data from its Alzheimer's disease clinical development portfolio at the upcoming Alzheimer's Association International Conference (AAIC) in Chicago (July 22-26). Data being presented are part of Biogen's research programs targeting several of the identified causes of Alzheimer's disease, focusing on early-stage disease. "The data to be presented at AAIC exemplify our belief that treatments are needed at the earliest stages of Alzheimer's disease to impact the underlying pathophysiology and delay disease p

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom